145 related articles for article (PubMed ID: 33283340)
1. Performance evaluation of immunoassay for infectious diseases on the Alinity i system.
Nam M; Song DY; Song SH; Roh EY; Shin S; Park KU; Song EY
J Clin Lab Anal; 2021 Mar; 35(3):e23671. PubMed ID: 33283340
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of four commercial analyzers for the serological screening of hepatitis A, B, C and HIV.
Kutvonen H; Jarva H; Lappalainen M; Kurkela S
J Clin Virol; 2022 Aug; 153():105219. PubMed ID: 35753174
[TBL] [Abstract][Full Text] [Related]
3. High-speed centrifugation rather than Lipoclear reagent can be used for removing the interference of lipemia on serological tests of infectious diseases: AIDS, hepatitis B, hepatitis C, and syphilis by chemiluminescent microparticle immunoassay.
Liu W; Li L; Yin M; Cao C; Song Y; Long X
J Med Virol; 2024 Feb; 96(2):e29385. PubMed ID: 38318918
[TBL] [Abstract][Full Text] [Related]
4. Performance Evaluation of Thyroid Function Tests on a Novel Chemiluminescent Microparticle Immunoassay System.
Ahn S; Cho Y; Lee SG; Kim JH
J Appl Lab Med; 2021 Mar; 6(2):367-377. PubMed ID: 33005941
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of analytical performance of Alinity i system on 31 measurands.
Seo JD; Song DY; Nam Y; Li C; Kim S; Lee JH; Lee K; Song J; Song SH
Pract Lab Med; 2020 Nov; 22():e00185. PubMed ID: 33204790
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the LIAISON®XL and ARCHITECT IgG, IgM, and IgG avidity assays for the diagnosis of Toxoplasma, cytomegalovirus, and rubella virus infections.
Genco F; Sarasini A; Parea M; Prestia M; Scudeller L; Meroni V
New Microbiol; 2019 Apr; 42(2):88-93. PubMed ID: 30994178
[TBL] [Abstract][Full Text] [Related]
7. Multiplex detection of IgM and IgG class antibodies to Toxoplasma gondii, rubella virus, and cytomegalovirus using a novel multiplex flow immunoassay.
Binnicker MJ; Jespersen DJ; Harring JA
Clin Vaccine Immunol; 2010 Nov; 17(11):1734-8. PubMed ID: 20861325
[TBL] [Abstract][Full Text] [Related]
8. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and experience from routine use of chemiluminescence assays for serological screening of blood and plasma donations on the Alinity s system and the Alinity i system, two new fully-automated immunoassay systems in Poland.
Kopacz A; Kubicka-Russel D; Liszewski G; Bukowska A; Samek S; Malka D; Łętowska M; Grabarczyk P
Pract Lab Med; 2024 Mar; 39():e00364. PubMed ID: 38328514
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.
Corrales I; Giménez E; Navarro D
Clin Vaccine Immunol; 2014 May; 21(5):684-8. PubMed ID: 24623623
[TBL] [Abstract][Full Text] [Related]
11. Performance characteristics of the high sensitivity Alinity i & ARCHITECT HBsAg Next Qualitative/Confirmatory assays.
Sickinger E; Braun HB; Meyer T; Schmid K; Daghfal D; Oer M; Schultess J
Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115033. PubMed ID: 32317130
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
13. Analytical validation of a quantitative method for therapeutic drug monitoring on the Alinity
Dubois N; Sqalli G; Gilson M; Charlier C
Ann Biol Clin (Paris); 2020 Apr; 78(2):147-155. PubMed ID: 32319943
[TBL] [Abstract][Full Text] [Related]
14. [Seroprevalence rates of Toxoplasma gondii, rubella, cytomegalovirus, syphilis, and hepatitis B, seroprevalences rate in the pregnant population in İstanbul].
Doğan K; Güraslan H; Özel G; Aydan Z; Yaşar L
Turkiye Parazitol Derg; 2014 Dec; 38(4):228-33. PubMed ID: 25732880
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the new ARCHITECT EBV assays considering different testing algorithms.
Sickinger E; Berth M; Vockel A; Braun HB; Oer M; Buenning C
Diagn Microbiol Infect Dis; 2014 Jul; 79(3):310-6. PubMed ID: 24809858
[TBL] [Abstract][Full Text] [Related]
16. Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis.
Guerrero-Ramos A; Patel M; Kadakia K; Haque T
Clin Vaccine Immunol; 2014 Jun; 21(6):817-23. PubMed ID: 24695777
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dried blood spot testing using the Abbott Alinity i.
Shepherd SJ; McLellan H; Bell J; Gunson RN
J Clin Virol; 2020 Nov; 132():104638. PubMed ID: 33049642
[TBL] [Abstract][Full Text] [Related]
18. Performance evaluation of LUMIPULSE G1200 autoimmunoanalyzer for the detection of serum hepatitis B virus markers.
Choi SJ; Park Y; Lee EY; Kim S; Kim HS
J Clin Lab Anal; 2013 May; 27(3):204-6. PubMed ID: 23440745
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays.
Lagrou K; Bodeus M; Van Ranst M; Goubau P
J Clin Microbiol; 2009 Jun; 47(6):1695-9. PubMed ID: 19339470
[TBL] [Abstract][Full Text] [Related]
20. Specificity and sensitivity of the IgM capture immunoassay: studies of possible factors inducing false positive or false negative results.
Briantais MJ; Grangeot-Keros L; Pillot J
J Virol Methods; 1984 Aug; 9(1):15-26. PubMed ID: 6501534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
